Table 1.
Analysis of Trp53bp1−/−/Atm−/− and control Atm−/− and Trp53bp1+/−/Atm−/− thymic lymphomas
| Mouse ID | Genotype | Gender | Age at death (weeks) | Tumor CD4/CD8 labelinga | Chromosome paint analysis
|
# chromosomes/ cell (range) b | |
|---|---|---|---|---|---|---|---|
| chrom 14 abnormalities (% metaphases) | chrom 12 abnormalities (% metaphases) | ||||||
| M#4 | Atm−/− | F | 16.5 | DP | n.d. | n.d. | n.d. |
| M#36 | Atm−/− | F | 16 | CD4 SP | n.d. | n.d. | n.d. |
| M#30 | Atm−/− | F | 23 | DP | Yes (98%) | Yes (98%) | 41.7 ± 0.5 (41–42) |
| M#35 | Atm−/− | M | 24 | DP | Yes (100%) | Yes (100%) | 40.0 ± 0.0 (40-40) |
|
| |||||||
| M#2 | Trp53bp1+/−/Atm−/− | M | 12 | DP | n.d. | n.d. | n.d. |
| M#5 | Trp53bp1+/−/Atm−/− | F | 18 | DP/DN | n.d. | n.d. | n.d. |
| M#49 | Trp53bp1+/−/Atm−/− | M | 12 | DP/CD4 SP | n.d. | n.d. | n.d. |
| M#10 | Trp53bp1+/−/Atm−/− | F | 27 | DP/CD4 SP | n.d. | n.d. | n.d. |
| M#70 | Trp53bp1+/−/Atm−/− | M | 14 | DP | n.d. | n.d. | n.d. |
|
| |||||||
| M#11 | Trp53bp1−/−/Atm−/− | M | 14.5 | DP | Yes (96%) | Yes (98%) | 39.8 ± 0.4 (39–40) |
| M#16 | Trp53bp1−/−/Atm−/− | M | 15 | CD4 SP | Yes (96%) | No | 41.7 ± 103 (38–44) |
| M#21 | Trp53bp1−/−/Atm−/− | M | 16.5 | DP | Yes (100%) | Yes (100%) | 40.8 ± 0.6 (40–42) |
| M#28 | Trp53bp1−/−/Atm−/− | M | 16 | DP | Yes (98%) | Yes (94%) | 40.1 ± 0.6 (39–41) |
| M#37 | Trp53bp1−/−/Atm−/− | M | 14 | DP | Yes (100%) | Yes (100%) | 40.0 ± 0.5 (39–41) |
| M#39 | Trp53bp1−/−/Atm−/− | M | 13.5 | DP/CD8 SP | Yes (92%) | Yes (92%) | 40.0 ± 0.2 (40–41) |
a
DP, double positive for CD4 and CD8; SP, single positive; mixed populations were observed in some tumors, as indicated.
b
average and standard deviation; n=20–30 metaphases per tumor; n.d., not done.